SAN FRANCISCO, Sept. 19, 2017 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases, today
announced that Matthew R. Patterson,
President and Chief Executive Officer, will present at the
following upcoming investor conferences:
- LEERINK Partners Roundtable Series: Rare Disease &
Immuno-Oncology
September 27, 2017, 11:30 am ET
Lotte New York Palace, New York,
NY
- Chardan Inaugural Gene Therapy Conference
October 10, 2017, 10:45 am ET
Westin Grand Central Hotel, New York,
NY
To access a live webcast of the presentations, please visit the
Events & Presentations page within the Investors + Media
section of the Audentes website. Replays of live webcasts
will be available on the Audentes website for approximately 30 days
following the conferences.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology
company focused on developing and commercializing gene therapy
products for patients living with serious, life-threatening rare
diseases. We have four product candidates in development,
AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM),
AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the
treatment of Pompe disease, and AT307 for the treatment of the
CASQ2 subtype of Catecholaminergic Polymorphic Ventricular
Tachycardia (CASQ2-CPVT). We are a focused, experienced and
passionate team committed to forging strong, global relationships
with the patient, research and medical communities.
For more information regarding Audentes, please
visit www.audentestx.com.
Audentes Contacts:
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com
Media Contact:
Paul Laland
415.519.6610
media@audentestx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-upcoming-investor-conferences-300521721.html
SOURCE Audentes Therapeutics, Inc.